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A B S T R A C T
Objectives: Identifying factors predictive of long-term morbidity should improve clinical planning
limiting disability and mortality associated with bipolar disorder (BD).
Methods: We analyzed factors associated with total, depressive and mania-related long-term morbidity
and their ratio D/M, as %-time ill between a first-lifetime major affective episode and last follow-up of
207 BD subjects. Bivariate comparisons were followed by multivariable linear regression modeling.
Results: Total % of months ill during follow-up was greater in 96 BD-II (40.2%) than 111 BD-I subjects
(28.4%; P = 0.001). Time in depression averaged 26.1% in BD-II and 14.3% in BD-I, whereas mania-related
morbidity was similar in both, averaging 13.9%. Their ratio D/M was 3.7-fold greater in BD-II than BD-I
(5.74 vs. 1.96; P < 0.0001). Predictive factors independently associated with total %-time ill were: [a] BD-
II diagnosis, [b] longer prodrome from antecedents to first affective episode, and [c] any psychiatric
comorbidity. Associated with %-time depressed were: [a] BD-II diagnosis, [b] any antecedent psychiatric
syndrome, [c] psychiatric comorbidity, and [d] agitated/psychotic depressive first affective episode.
Associated with %-time in mania-like illness were: [a] fewer years ill and [b] (hypo)manic first affective
episode. The long-term D/M morbidity ratio was associated with: [a] anxious temperament, [b]
depressive first episode, and [c] BD-II diagnosis.
Conclusions: Long-term depressive greatly exceeded mania-like morbidity in BD patients. BD-II subjects
spent 42% more time ill overall, with a 3.7-times greater D/M morbidity ratio, than BD-I. More time
depressed was predicted by agitated/psychotic initial depressive episodes, psychiatric comorbidity, and
BD-II diagnosis. Longer prodrome and any antecedent psychiatric syndrome were respectively
associated with total and depressive morbidity.
C 2017 Elsevier Masson SAS. All rights reserved.
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Major mood disorders are leading contributors to disease-
burden due to their high prevalence and risks of recurrences,
sustained morbidity, and mortality from suicide and comorbid
medical illnesses [1]. Factors reported to be associated with* Corresponding author. Child Psychiatry Unit, Department of Neuroscience,
Bambino Gesu` Children’s Hospital, IRCCS, Rome (Italy).
E-mail address: giuliaserra@gmail.com (G. Serra).
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0924-9338/C 2017 Elsevier Masson SAS. All rights reserved.morbidity and disability in mood disorders include symptomatic
severity in acute episodes, more recurrences and hospitalizations,
financial and legal problems, co-occurring anxiety disorders, and
delay of or nonadherence to treatment [2–5]. Findings from a
recent meta-analysis involving 25 studies indicated similarly high
levels of long-term morbidity (44.4% [CI: 39.6–49.2] of months ill/
time at risk, overall) in clinically treated bipolar disorder (BD-I, BD-
II) and major depressive disorder (MDD) patients [1]. Notably, in
BD subjects, 70%–80% of this unresolved morbidity was depressive
(31% in BD-I, 36% in BD-II), whereas mania-like morbidity,
averaged much less among BD-I (10%) and BD-II (6%) subjects [1].
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and especially depressive morbidity, the need to identify factors
that can inform prognosis and predict future levels and types of
morbidity is of great clinical importance. Encouraging findings
arise from the strong predictive power of the type of initial
affective episode in BD, notably for the predominant long-term
polarity (excess of depressive or mania-like recurrences per year at
risk). That is, depressive polarity was in large excess among
patients presenting with an initial depressive, mixed (DSM-IV), or
anxious episode, whereas an excess of mania-like recurrences was
more likely to follow an initial manic, hypomanic, or psychotic
episode both in type I and II BD subjects [6,7]. Other factors have
been reported to be related to an initial depressive episode and to a
later prevalent depressive polarity, and to predict a less favorable,
long-term course. These include a predominant Depression-
Mania-euthymic Interval (DMI) illness-course (contrasted to a
Mania-Depression-Interval [MDI] course), a tendency toward a
rapid cycling or continuous circular course, more use of anti-
depressants, more suicidal thoughts and actions, more mixed
features, and a co-occurring personality disorder diagnosis [6,8].
Little has been reported about juvenile clinical features as
predictors of the types and severity of future adult morbidity in BD,
although it is recognized that adult mood disorders with a juvenile
onset, generally are more severe and more recurrent than similar
illnesses starting in adult years [9–13]. In particular, onset of BD in
childhood or adolescence was associated with a greater number of
future episodes, higher percent-time ill, higher risk of rapid
cycling, more severe manic and depressive episodes [10,14], and
greater rates of comorbid psychiatric disorders, especially anxiety
and substance use disorders, as well as greater likelihood of suicide
attempts and violent behavior [14].
Consistent and concordant findings have linked early onset of
mood disorder to less favorable long-term outcomes, but details of
relationships between early onset or longer delay of diagnosis and
appropriate treatment, and particular aspects of future morbidity
remain uncertain or inconsistent in BD. For example, whether
longer delay of diagnosis and treatment yields a less favorable
long-term outcome is debated. Such a relationship is clinically
plausible [15], but the specific question of whether early history
exerts a dominant influence on future response to treatment seems
increasingly unlikely in both BD [16–20] and MDD [21].
Given the limited information about early factors associated
with long-term morbidity in adult BD, the present study aimed to
identify demographic, family history, and antecedent juvenile or
early adult clinical features associated with time in overall and
polarity-specific morbidity in a sample of adult BD subjects
observed prospectively and systematically over several years.
2. Methods
Historical and prospective data obtained during clinical
assessment and treatment were extracted from detailed, semi-
structured clinical records of adult outpatients diagnosed with BD,
evaluated and treated for many years by the same mood disorder
expert, the late Athanasios Koukopoulos, M.D., at the Lucio Bini
Mood Disorder Center which he had founded in Rome. At clinic
intake, participants provided written, informed consent for
potential research analysis and anonymous reporting of clinical
findings in aggregate form, in accord with Italian ethical
requirements. Two investigators (GS and LDC) selected patients’
records in random order among those of subjects with a final DSM-
IV-TR diagnosis of BD (type I or II). Study subjects were drawn at
alphabetically from a total of approximately 1000 bipolar patients
evaluated and followed by Dr. Koukopoulos for at least one year.
Records had to include details of family history, past history,features of current and previous illness including comorbid
syndromes (anxiety, eating, or substance abuse disorders) based
on at least one year of repeated, systematic assessments and
observation at the study center. Only records with required
information were selected (leading to the exclusion of 5.0% of
records with missing required information).
Dr. Athanasios Koukopoulos systematically followed and
treated all study subjects for several years before this study was
designed. His diagnoses following DSM-IV-TR criteria were later
confirmed for this study by direct examination (the majority were
confirmed based on live clinical reassessments and some from
chart reviews) by one other senior research psychiatrist at the
study center (Dr. Gabriele Sani or Prof. Paolo Girardi) using
the Structured Clinical Interview for DSM-IV-TR-Patient Edition
(SCID-I/P).
If diagnoses were not consistent, more data were gathered and
diagnostic assessment was continued until final consensus was
reached or the potential participant was excluded. To maximize
reliability, each chart was reviewed independently by two
investigators (LDC and AEK) and required data were extracted
from clinical records and summarized in structured research forms
by the two investigators, working to consensus with a third
investigator (GS).
2.1. Subject assessment
Historical and prospective information was collected in semi-
structured assessments used at Lucio Bini Mood Disorder Center
since 1974 with mood disorder patients at first evaluations and
during long-term follow-up. Assessments  are based on DSM
criteria and on detailed clinical evaluation (not on simple yes/no
answers to structured questions). Wording of questions posed
could be changed to improve understanding, and evaluations
were routinely supplemented with information from family
members or close friends during at least one visit, as well as by all
available medical documentation. Data collected about education,
employment, past, social and family history were entered into
preprinted medical record forms. Affective temperaments were
evaluated clinically, following criteria described by Akiskal &
Mallya [22].
Current and historical assessments included retrospective
evaluation of juvenile psychiatric symptoms, syndromes, or
behavioral abnormalities, with approximate ages at their appear-
ance, as well as estimates of their intensity and approximate
duration. In addition, details of the history of BD prior to entering
the study center were recorded routinely, including the type of first
episode, number and types of subsequent affective episodes,
treatments, hospitalizations, levels of impairment, and informa-
tion about suicidal behaviors.
2.2. Long-term follow-up
During follow-up at the study center, participants were
assessed at 1–12 week intervals, as required clinically, with
semi-structured interviews routinely supplemented with stan-
dardized ratings of for depressive (21-item Hamilton Depression
Rating Scale [HDRS-21]) [23] and (hypo)manic features (Young
Mania Rating Scale [YMRS]) [24]. During follow-up the number,
type (polarity and subtype), duration and severity of major
affective episodes were recorded in life-charts used at the center
since 1980 [25], as well as information about treatments,
psychiatric hospitalizations, and the occurrence, timing, methods
and circumstances of lifetime suicidal or self-injurious behaviors.
Mania-related morbidity included manic, hypomania and mixed
episodes (DSM-IV-TR) with and without psychosis whereas
depressive morbidity included simple depression as well as
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as described by Koukopoulos [26] during the years at risk.
2.3. Time at risk
Time at risk following initial expression of overt syndromal
illness was calculated from the start of a first-lifetime major
affective episode to the last observation at the study center.
Systematically, retrospectively and prospectively collected clinical
assessment data included in records and life-charts allowed
quarterly estimates of episode counts and durations, and estimates
of the percentage of months of mania-related illness, depression,
and all affective illness during the total time at risk, to support life-
charting.
2.4. Clinical antecedents
Antecedent events considered were psychopathological symp-
toms, altered or abnormal behaviors, or non-affective syndromes
identified as occurring prior to a first major affective episode – all
retrospectively assessed [27]. Juvenile antecedent symptoms and
signs (not DSM-syndromes) included clinical features occurring
during childhood (ages 1–12) or adolescence (ages 13–18 years)
with estimated duration, intensity, and with single or recurrent
pattern sustained over several juvenile years that were not severe
enough to satisfy DSM-IV-TR criteria for a psychiatric disorder [27].
2.5. Antecedent non-affective syndromes
We also considered antecedent non-affective syndromes
meeting DSM-IV-TR diagnostic criteria occurring before a first
major affective episode such as anxiety disorders (panic disorder,
generalized anxiety disorder, obsessive compulsive disorder, or
phobia), eating disorders (anorexia or bulimia nervosa), and
substance abuse or dependence disorders.
2.6. Analyses
Data analyses were made by a co-investigator (RJB) held
independent of data-collection and clinical assessments. Repor-
ted averages are means with standard deviation ( SD) or 95%
confidence interval (CI). We analyzed factors associated with
morbidity as the percentage of months of total, depressive (D),
and mania-related (M) affective illness during the time at risk, as
well as the D/M ratio. These outcomes were analyzed in preliminary
bivariate analyses (Anova) with t-scores for continuous variables or
contingency tables [x2] for categorical measures, followed by
stepwise, multivariable, linear regression modeling to provide slope
functions (b with CI) and corresponding t-scores for association with
factors of interest. Analyses used commercial statistical software
(Stata.131; StataCorp, College Station, TX) using data spreadsheets
based on Excel (Microsoft Corp., Redmond, WA) and Statview.51
(SAS Institute; Cary, NC).Table 1
Morbidity in 207 bipolar disorder subjects.
Features Diagnostic groups (% or mean  S
A. BD-I
(n = 111)
B
(
At risk (years) 18.9  10.9 1
Total % time ill 28.4  22.9 4
Mania % time ill 13.9  13.9 1
Depression % time ill 14.3  16.8 2
Depression/Mania (D/M) ratioa 1.96  4.39 5
a Computed as mean of individual ratios.3. Results
3.1. Subjects
The study sample included a total of 207 consenting, randomly
selected, adults diagnosed with DSM-IV-TR bipolar disorder (BD),
type I (n = 111) or II (n = 96), enrolled at the study center at adult
ages averaging 42.2  15.4 years; 62.0% were women. All partici-
pants were followed at clinically determined intervals of 1–12 weeks,
assessed repeatedly, and treated by Dr. Koukopoulos for an average of
7.45  8.03 years.
3.2. Morbidity in mood disorder subjects
During the time at risk (from the first affective episode to the
last visit at the center), we assessed estimates of total, mania-
related, and depressive morbidity, estimated as percentage of
months during an average of 18.9  12.9 years. Time at risk was
similar between diagnostic groups (Table 1). Total morbidity
represented 33.9  25.5% of time at risk among all BD subjects,
based on the presence of major affective episodes. This measure was
significantly higher among BD-II (40.2  27.1%) than BD-I subjects
(28.4  22.9%; Table 1).
Depressive morbidity included simple major depressive epi-
sodes and episodes with mixed, agitated, or psychotic features, all
of which accounted for 19.8  19.1% of time at risk, or a majority
(58.4%) of the 33.9% of time estimated for total morbidity. Depressive
morbidity was 1.9-times greater among BD-II (26.1  19.7%) than BD-
I subjects (14.3  16.8% of time; Table 1). Mania-related morbidity
(hypomanic, manic, and mixed episodes with or without psychosis)
averaged 14.0  15.3% of time at risk among BD subjects and did not
differ significantly between BD-I and -II cases (13.9  13.9% vs.
14.2  17.0%; Table 1). The ratio of % of time in depressive/mania-
related morbidity (D/M) was 3.67  6.93 for all BD subjects, and 2.9-
times greater in BD-II than BD-I subjects (5.74  8.74 vs. 1.96  4.39;
Table 1).
3.3. Factors associated with total morbidity
Total morbidity was associated with fewer years at risk, but
probably as an artifact of ‘‘dilution’’ of non-chronic morbidity (as %-
time ill) with longer exposure time. Total morbidity was 1.4-times
greater in BD-II than BD-I subjects (40.2% vs. 28.4%; Table 1).
Additional factors associated in preliminary bivariate analyses
included the following: longer prodromal latency from first
antecedent (symptoms or non-affective syndromes) to first major
affective episode, shorter delay of mood-stabilizer treatment, more
hospitalizations/year, co-occurrence of other psychiatric disorders,
the occurrence of any psychiatric syndrome prior to a first episode
of depression or mania, older age at first major affective episode,
presenting initially in hypomania or severe (agitated-mixed or
psychotic) depression, a childhood history of insomnia, and family
history of anxiety (Table 2a). Several of these measures co-varyD) P-value (statistic)
. BD-II
n = 96)
C. All BD
(n = 207)
A vs. B
9.5  13.0 18.4  12.9 0.20 (1.29)
0.2  27.1 33.9  25.5 0.003 (2.95)
4.2  17.0 14.0  15.3 0.87 (0.17)
6.1  19.7 19.8  19.1 0.02 (2.38)
.74  8.74 3.67  6.93 < 0.0001 (4.01)
Table 2a
Factors associated with total %-time ill in 207 bipolar disorder subjects.
Factors % of time of ill ( SD) or b [95% CI] t-score P-value
Years at riska –0.936 [–1.21 to –0.67] 6.83 < 0.0001
Years from first major affective episode to mood-stabilizer treatment –0.686 [–1.05 to –0.325] 3.74 0.0002
Bipolar types 3.42 0.001
Type I 28.4  22.9
Type II 40.2  27.1
Years from first antecedent to first major affective episode 0.533 [0.217–0.850] 3.32 0.001
Hospitalizations/year 13.6 [4.93–22.2] 3.10 0.002
Psychiatric comorbidity 2.71 0.007
Present 41.1  26.2
Absent 30.8  24.7
Antecedent syndromes 2.37 0.02
Any 38.7  26.2
None 30.3  24.5
Age at first major affective episodea 0.372 [0.041–0.703] 2.22 0.03
First affective episode type 1.71 0.04
Hypomania 42.3  23.1
Agitated/psychotic depression 39.6  29.7
Simple depression 30.5  23.2
Mania/mixed 29.9  26.3
Insomnia at age < 12 2.11 0.04
Present 51.3  22.5
Absent 33.1  25.4
Family history of anxiety 2.09 0.04
Present 39.8  26.0
Absent 31.6  25.1
a Years at risk produces an artifactual increase in apparent %-time ill in non-chronic illness, and confounds age at first major affective episode and probably hospitalization
rate.
Table 2b
Multivariable linear regression model: factors associated with total %-time ill.
Factors b [95% CI] t-score P-value
Bipolar II > I diagnosis 10.4 [3.76–17.1] 3.08 0.002
Longer from first antecedent to first major affective episode 2.22 [1.32–7.07] 2.87 0.004
Psychiatric comorbidity 9.88 [2.67–17.1] 2.70 0.007
Other factors not significantly associated with %-time ill included: sex; substance misuse; any comorbid medical disorder; family history of major affective disorder or
suicide; suicide attempted and number of suicide attempts/years at risk; psychiatric hospitalization; juvenile symptoms (anxiety, depressive, heightened emotionality, mood
swings, low self-esteem, phobia, withdrawn-asocial); as well as age at first antecedent or first major affective episode; total number of antecedents/years at risk; years from
first antecedent to first mood-stabilizer treatment; multivariable model excludes years at risk from first episode, which has a strong ‘‘diluting’’ effect on morbidity expressed
as % of time/year, we also excluded hospitalizations/year as probably confounded by both time at risk and by illness severity.
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dent and may be influenced artifactually by total time ill (notably
age at first affective episode), whereas other time-dependent
measures remained significant after adjusting for years of illness.
Of note, total morbidity was not correlated with suicide attempt
ever (%time ill in suicide attempters 33.2  25.8 versus non-
attempters 35.6  24.9; t = 0.59, P = 0.57) and with number of suicide
attempts/years at risk (b = 0.132 [–2.13 to 139]; t = 1.91, P = 0.06).
Multivariable linear regression modeling found three factors to
be significantly and independently associated with total percent-
time ill, ranking by significance: [a] diagnosis of BD-II, [b] longer
prodromal latency from first antecedent to a first major affective
episode; [c] comorbid psychiatric disorder (Table 2b).
3.4. Factors associated with depressive morbidity
Again, shorter exposure led to greater proportions of time
depressed, and BD-II subjects spent 1.8-fold more time depressed
than BD-I cases, based on preliminary bivariate analyses (Table 3a).
Other factors preliminarily associated with %-time depressed
included: presence of any psychiatric comorbid condition,
hospitalization rate, initial agitated/psychotic depression or
hypomania more than mania, an antecedent non-affective
syndrome before the first major affective episode (especially an
anxiety disorder), depressive polarity of first major affectiveepisode, longer prodromal latency from initial antecedent and a
first-lifetime major affective episode, a rapidly or continuously
cycling or erratic illness-course, and shorter latency from first
major affective episode to start of mood-stabilizer treatment
(Table 3a). Again, some of these time-related factors co-vary with
illness severity in general, and others appeared to be artifactually
influenced by total exposure time, and became nonsignificant
when adjusted for years ill, including hospitalizations/year, and
time from first episode to treatment. As total morbidity, also
depressive morbidity was not correlated with suicide attempt ever
(t = 0.90, P = 0.37) and with number of suicide attempts/years at
risk (t = 1.43, P = 0.16).
Multivariable linear regression modeling indicated that four
factors remained significantly and independently associated with
long-term percent-time depressed, ranking by significance as: [a]
BD-II > BD-I diagnosis; [b] having an antecedent non-affective
syndrome before the first major affective episode, [c] having a
psychiatric comorbidity and [d] history of an agitated or psychotic
depressive first episode (Table 3b).
3.5. Factors associated with mania-related morbidity
The expected ‘‘dilution’’ effect of longer exposure time was
found again. There was no difference in time spent in mania or
hypomania, long-term, among BD-I and BD-II subjects. Additional
Table 3a
Factors associated with %-time depressed in 207 bipolar disorder subjects.
Factors % Time Ill ( SD) or b [95% CI] t-score P-value
Bipolar type 4.63 < 0.0001
Type I 14.3  16.8
Type II 26.1  19.7
Years at risk –0.482 [–0.695 to 0.269] 4.45 < 0.0001
Psychiatric comorbidity 3.71 < 0.0001
Present 27.1  22.9
Absent 16.7  16.3
Hospitalizations/years at risk 9.57 [4.35–14.8] 3.62 < 0.0001
First affective episode type 2.76 < 0.0001
Agitated/psychotic depression 29.6  27.0
Hypomania 23.6  17.7
Simple depression 20.3  16.6
Mania/mixed 11.6  14.7
Antecedent psychiatric disorders 3.23 0.002
Present 24.7  22.0
Absent 16.2  15.7
Antecedent anxiety disorder 2.63 0.009
Present 26.0  22.9
Absent 17.9  22.9
Depressive polarity at first major affective episode 6.72 [1.56–11.9] 2.57 0.01
Years first antecedent to first major affective episode 0.310 [0.068–0.546] 2.54 0.01
Predominant course-type 1.70 0.02
Continuously or rapidly cycling 26.9  19.3
Irregular 22.6  21.5
DMI 19.6  22.3
Seasonal 19.2  16.5
MDI 13.0  12.7
Years from first major affective episode to mood-stabilizer treatment –0.281 [–0.555 to –0.007] 2.03 0.04
Table 3b
Multivariable linear regression model: factors associated with %-time depressed.
Factors b [95% CI] t-score P-value
Bipolar II > I diagnosis 11.2 [6.40–16.0] 4.61 < 0.0001
Any antecedent psychiatric syndrome before first major affective episode 6.90 [1.83–11.9] 2.69 0.008
Any psychiatric comorbidity 7.18 [1.69–12.7] 2.58 0.01
First episode: agitated or psychotic major depression 8.23 [1.52–14.9] 2.42 0.02
Multivariable model excludes years at risk from first episode, which has a strong ‘‘diluting’’ effect on morbidity expressed as %-of time ill/year, as well as latency to first mood-
stabilizer treatment, and also excludes hospitalizations/year as probably confounded by both time at risk and by illness severity. Other factors not significantly related to %-
time depressed included: sex; substance misuse; any comorbid medical disorder; family history of major affective disorder or suicide; attempted suicide and number of
suicide attempts/years at risk; ever psychiatrically hospitalized, juvenile symptoms (anxiety, depressive, heightened emotionality, insomnia, mood swings, low self-esteem,
phobia, withdrawn-asocial); number of antecedents/years at risk; age at first antecedent and at first major affective episode.
Table 4a
Factors associated with %-time in manic, hypomanic, or mixed episodes among 207 bipolar disorder subjects.
Factors % Time Ill ( SD) or b [95% CI] t-score P-value
Years of follow-up –0.461 [–0.629 to –0.292] 5.40 < 0.0001
First affective episode polarity 3.95 < 0.0001
[Hypo]manic 18.3  18.3
Depressive 10.2  10.8
Hospitalizations/years at risk 9.57 [4.35–14.8] 3.62 < 0.0001
Years from first major episode to mood-stabilizer treatment –0.420 [–0.640 to –0.200] 3.77 0.0002
Years from first antecedent to first major affective episode 0.230 [0.037–0.422] 2.35 0.02
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morbidity included: a manic or hypomanic first-lifetime major
affective episode (1.8-fold more time in later mania-like illness
than depression), more hospitalizations/year, years from first
major affective episode to start of mood-stabilizer treatment,
and prodromal time from first antecedent to first major
affective episode (Table 4a). Factors that became nonsignificant
when co-varied with total exposure years included: prodromal
years from antecedent to first major affective episode, and years
from first major affective episode to start of mood-stabilizer
treatment.
By multivariable linear regression modeling, two factors
remained independently associated with long-term mania-relatedmorbidity: [a] fewer years ill, and [b] a mania-like first major
affective episode (Table 4b).
3.6. Factors associated with ratio of time in depression/mania (D/M)
The ratio of depressive to mania-related morbidity (D/M) was
not associated with total years of illness. However, the ratio was
2.9-times greater among BD-II than BD-I subjects (Tables 1 and 5a),
paralleling the excess of depressive morbidity among BD-II cases
(Tables 1 and 3a). Several other factors also were significantly
associated with a higher D/M ratio based on bivariate analyses. In
addition to BD-II diagnosis, these included: depressive polarity at
first-lifetime major affective episode, a predominant DMI vs. MDI
Table 4b
Multivariable linear regression model for factors associated with percent-time in mania-like illness.
Factors b [95% CI] t-score P-value
Fewer years ill 2.54 [1.76–4.52] 4.50 < 0.0001
First-lifetime episode [hypo]manic 5.54 [1.48–9.60] 2.69 0.008
Multivariate modeling excluded hospitalization rate as closely related to illness severity itself. Factors not significantly related to %-time in mania-like illness include:
diagnosis (type I vs. II); sex; substance misuse; any comorbid psychiatric or medical disorder; family history of major affective or anxiety disorder or suicide; attempted
suicide and number of suicide attempts/years at risk; ever psychiatrically hospitalized; juvenile psychiatric symptoms (anxiety, depressive, heightened emotionality,
insomnia, mood swings, low self-esteem, phobia, withdrawn-asocial) or syndromes; number of antecedents/years at risk; age at first antecedent or at first major affective
episode; years from first antecedent to first mood-stabilizer treatment; and course-type.
Table 5a
Factors associated with ratio (D/M) of %-time in depressive/mania-like illness among 207 bipolar disorder subjects.
Factors D/M ( SD) or b [95% CI] t-score P-value
Polarity of first major affective episode 4.44 < 0.0001
Depressive 5.67  9.01
[Hypo]manic 1.53  2.19
Course-type 4.02 < 0.0001
Depression-Mania-Interval (DMI) 7.28  11.0
Mania-Depression-Interval (MDI) 1.37  1.87
Bipolar disorder type 4.01 < 0.0001
Type I 1.96  4.39
Type II 5.72  8.66
First affective episode type 2.74 < 0.0001
Agitated/psychotic depression 7.14  10.1
Simple major depression 5.10  8.47
Hypomania 2.28  2.97
Mania/mixed 1.05  1.32
Years from first major affective episode to first mood-stabilizer treatment 0.182 [0.085–0.280] 3.70 0.0003
Temperament 2.52 0.0004
Anxious 10.8  15.6
Cyclo- or hyperthymic 3.26  5.59
Irritable 1.51  1.35
Dysthymic 1.05  0.82
Years from first antecedent to first mood-stabilizer treatment 0.082 [0.012–0.153] 2.29 0.02
Antecedent anxiety disorder 2.07 0.04
Present 5.49  8.94
Absent 3.12  6.17
Older at first mood-stabilizer treatment 0.077 [0.002–0.152] 2.03 0.04
Table 5b
Multivariable linear regression model of factors associated with D/M morbidity ratio.
Factors b [95% CI] t-score P-value
Anxious temperament 7.25 [3.78–10.7] 4.13 < 0.0001
Depressive polarity of first major affective episode 3.41 [1.44–5.39] 3.42 0.001
Bipolar II > I diagnosis 2.35 [0.36–4.35] 2.33 0.02
Other factors not significantly related to D/M included: sex; any substance misuse; any comorbid medical or psychiatric disorder; family history for major affective or anxiety
disorder or suicide; prior suicide attempt or number of attempts/years at risk; psychiatric hospitalization or number of admissions/years at risk; years at risk (from first
episode to present); juvenile symptoms (depressive, mood swings, anxiety, heightened emotionality, low self-esteem, phobia, insomnia, withdrawn-asocial), juvenile eating
or substance abuse disorders, number of antecedents/years at risk; and latency from first antecedent to first major affective episode.
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features, latency from first major affective episode to mood-
stabilizer treatment, anxious temperament, years from first
antecedent and initial mood-stabilizer treatment, anxiety disorder
before first major mood episode, and being older at initial
treatment with a mood-stabilizer (Table 5a).
In multivariable linear regression modeling, three factors
remained associated independently with a higher D/M ratio. By
statistical significance, they ranked as: [a] anxious temperament;
[b] depressive polarity of first major affective episode, and [c] BD-II
diagnosis (Table 5b).
4. Discussion
Total morbidity observed in the present clinically treated study
sample of 207 BD patients accounted for 34% of time at risk. This
level of clinically treated morbidity was somewhat lower thancomparable levels averaging 43.5% in BD subjects reported in a
recent review of morbidity in clinically treated major affective
disorder subjects [1]. The discrepancy probably reflects characte-
ristics of patients sampled and in their treatment, but also a much
longer duration of exposure in the present study (18 years),
compared to the average of 9.4 years from previous studies
[1]. Longer exposure was found in the present study to be a major
factor leading to lower proportions of time ill in the typically
intermittent disorders considered, as noted previously [1,18,28]. In
the present data, proportions of total, depressive and manic time ill
all declined highly significantly with longer exposure (Tables 2a,
3a, 4a). This tendency does not seem consistent with the view that
major affective disorders may worsen and show an acceleration of
recurrences over time [6,29]. Instead, we propose that prolonged
observation (denominator) tends to ‘‘dilute’’ intermittent morbid-
ity by including increasing amounts of time in more or less
euthymic states (‘‘temporal dilution’’ artifact). This concern led to
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(Tables 2b, 3b, 4b).
In addition, association of higher %-time ill with the rate of
psychiatric hospitalizations/years at risk but not with hospitaliza-
tion at any time (Table 2a), suggests that this measure, too, was
influenced by overall time at risk. Other time-related measures
also may be influenced artifactually by total exposure time,
including the prodromal latency from initial antecedents to the
first major affective episode, and the latency from first episode to
initial mood-stabilizer treatment (Table 2a). Perhaps counter-
intuitively, the latency to treatment was negatively associated
with %-time ill (shorter delay of treatment, worse long-term
morbidity), probably owing to earlier intervention for more severe
illness including acute mania. These preliminary associations with
long-term morbidity/time were no longer significantly associated
after adjusting for total exposure time.
We also propose that an unexpected, selective, inverse
relationship of younger age at first major affective episode
predicting less long-term morbidity (Table 2a) is a further
manifestation of the effect of diluting intermittent morbidity with
longer time at risk. This interpretation is supported by a very
strong inverse relationship between onset-age and duration of
illness from onset to the end of follow-up, and loss of significant
association of onset-age with long-term morbidity/time with
adjustment for total exposure time. It is important to clarify that
the apparent association of shorter overall exposure time with
more intense morbidity/time is to be contrasted to consistent
findings that juvenile onset of major mood disorders usually is
followed by an unfavorable later illness-course [9–13].
Another notable finding is that BD-II subjects had 1.42-fold
higher levels of overall morbidity than BD-I cases; 64.9% of this
unsolved morbidity was depressive in BD-II subjects and 50.4% in
BD-I (Table 1), compared to more than 70% reported previously
[1]. It also followed that the ratio of D/M morbidity was 2.9-times
greater in BD-II than BD-I subjects (Table 1). These findings add to
growing impressions that BD-II is a more severe illness than
sometimes is supposed, including rates of suicidal behavior that
are similar to those in BD-I patients [28].
The polarity and type of first major affective episode strongly
predicted a predominance of the same polarity during follow-up,
consistent with previous findings with other samples [6,7]. A new
finding is that a first-lifetime agitated, mixed or psychotic
depressive episode was strongly associated with both high levels
of long-term depressive morbidity (29.7  27.0%) and prevalent
depressive polarity (D/M = 7.14  10.1) in BD subjects. Contrarily,
manic polarity at the first major affective episode in BD was
associated with a high percentage of later time in mania-like
morbidity (18.3  18.3%) as well as a much less time in depression
than among subjects who started with depression (D/M
ratio = 1.05  0.82 vs. 7.14  10.1, respectively). It should also be
noted that the D/M ratio based on %-time ill is slightly greater than
that calculated by dividing the number of depressive/manic episodes
per year [7] – probably reflecting the typically shorter duration of
manic than depressive episodes.
In addition, juvenile factors also were associated with subse-
quent adult levels and types of morbidity in BD. A non-affective
syndrome, particularly an anxiety disorder, before the first major
affective episode was associated with greater total and depressive
morbidity and a predominance of depression over mania, based on
bivariate analyses (Tables 3a, 5a). These associations are consistent
with previous findings that BD subjects presenting first with an
anxiety disorder have a higher D/M ratio than subjects with other
types of onset [7]. Moreover, an anxious temperament was highly
significantly and independently associated with prevalent depres-
sive polarity, with D/M ratios 7- to 10-times higher than with other
temperament types (Table 5). That is, anxious temperament andjuvenile anxiety symptoms and syndromes predicted higher levels
of later depressive morbidity.
Predominant course-patterns also were significantly associated
with the prevalent polarity type, although their prospective,
predictive value is very limited. Subjects presenting with a chronic
illness-course were manic for 40% of time at risk compared to the
14% of time in all BD subjects, whereas subjects with a rapid cycling
or continuous circular course presented the highest levels of
depressive morbidity (27%) compared to 19% in the total BD
sample. Moreover, rapid cycling was associated more with
depressive (26.9 [CI: 19.8–34.0]%) than manic morbidity
(15.0 [10.3–19.7] %-time ill). In addition, those with a predominant
DMI episode-sequence were much more likely to present initially
in depression and to have predominant depressive polarity, as
reported previously [7].
Antecedent syndromes, as well as co-occurring psychiatric
disorders, and especially anxiety and eating disorders, were
strongly associated with total and depressive morbidity in BD
subjects (Tables 2a, 3a) and with prevalent depressive polarity
(Table 5a). These relationships are not surprising as BD patients
with Axis I comorbidity usually present greater illness severity and
proportion of time ill, as well as responding less favorably to mood-
stabilizing treatment [30–34]. Overuse of antidepressants as anti-
anxiety treatments for such comorbid BD patients may risk
worsening and destabilizing effects [35].
Factors associated with long-term %-time ill, surprisingly, were
found to be dissimilar to factors predicting diagnostic outcomes
and suicide attempts, based on developmental psychopathology
occurring during very early ages. Whereas family history of
affective disorders or suicide, temperamental characteristics, and
juvenile symptoms appear to have some value in predicting
diagnosis (BD vs. MDD) and later suicidal behaviors [27,36], these
same factors had little value for predicting the type and intensity of
future, long-term morbidity in mood disorder patients in the
present findings (Tables 2–5). Importantly however, early cha-
racteristics of syndromal mood disorders did predict later
morbidity. These included the polarity of first-lifetime episodes,
initial complex versus simple depression, early anxiety features,
and later comorbidity with non-affective psychiatric disorders. We
propose that diagnosis and suicidal behaviors have roots in very
early and even congenital factors, whereas prognosis of types and
intensities of morbidity probably reflect factors that include
experiential and environmental events as well as effects of
treatment.
4.1. Limitations
This study was limited mainly by retrospective identification of
early, predictive events, sometimes occurring years prior to entry
into the study site in adulthood, followed by long-term, prospec-
tive follow-up, during which other correlates of morbidity were
identified. All these factors may have been influenced by a recall
bias. However, since the comparisons were between diagnostic
groups, the possible bias may have been equally distributed among
the groups.
5. Conclusions
In summary, we found that the total %-time ill was greater
among BD-II (40.2%) than BD-I subjects (28.4%). Mania-related
morbidity averaged 14.0% of follow-up time in both types I and II
BD, whereas the prevalence of depressive morbidity was much
greater, and consequently the ratio of time in depression/mania-
like illness (D/M) was nearly three-times greater in BD-II than BD-I
subjects. Predictive factors associated with total %-time ill were:
G. Serra et al. / European Psychiatry 43 (2017) 35–4342[a] BD-II diagnosis, [b] longer prodromal latency from first
symptoms to first major affective episodes, and [c] comorbid
psychiatric disorders. Associated with %-time depressed were: [a]
BP-II diagnosis, [b] antecedent non-affective psychiatric syndro-
mes, [c] psychiatric comorbidity, and [d] agitated or psychotic
depressive first episode. Associated with %-time in mania-like
illness were: [a] shorter overall years at risk, and [b] a mania-like
first affective episode. The ratio D/M was greater with: [a] anxious
temperament, [b] depressive first episode, and [c] BD-II diagnosis.
These findings support the impression that important dimensions
of later morbidity can be predicted by factors identified early in the
course of BD, including features present before or during a first
major affective episode. Such predictive relationships should have
clinical value in helping to identify and guide treatment needs
early in the course of BD.
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